Targeting the epidermal growth factor receptor in solid tumor malignancies. (Q37990044)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Targeting the epidermal growth factor receptor in solid tumor malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Mette K Nedergaard

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Hans S Poulsen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

83-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22385404%20AND%20SRC:MED&resulttype=core&format=json

EGFR family: structure physiology signalling and therapeutic targets

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Rat Transforming Growth Factor Type 1: Structure and Relation to Epidermal Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structure and function of human amphiregulin: a member of the epidermal growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A Heparin-Binding Growth Factor Secreted by Macrophage-Like Cells That Is Related to EGF

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structure-based view of epidermal growth factor receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Spatial control of EGF receptor activation by reversible dimerization on living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal growth factor receptor signaling in liver cell proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The EGFR network in bone biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Transgenic and knock-out mice for deciphering the roles of EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Mechanisms for oncogenic activation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal growth factor receptors on ependymomas and other brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The natural history of EGFR and EGFRvIII in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Immunotoxin therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

CI-1033, a pan-erbB tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

The cancer vaccine roller coaster

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Could autoimmunity be induced by vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

A causal link between lymphopenia and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Autoimmunity during lymphopenia: a two-hit model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599760-000000000-00000